Genenta Science S.p.A. (NASDAQ:GNTA) Short Interest Update

Genenta Science S.p.A. (NASDAQ:GNTA) was the recipient of a significant decrease in short interest during the month of February. As of February 28th, there was short interest totalling 1,500 shares, a decrease of 40.0% from the February 13th total of 2,500 shares. Based on an average daily volume of 10,400 shares, the short-interest ratio is currently 0.1 days. Approximately 0.0% of the company’s stock are short sold.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Genenta Science stock. Allianz SE purchased a new position in Genenta Science S.p.A. (NASDAQ:GNTA) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 103,250 shares of the company’s stock, valued at approximately $444,000. Allianz SE owned about 0.56% of Genenta Science at the end of the most recent quarter. 15.13% of the stock is owned by institutional investors and hedge funds.

Genenta Science Price Performance

Shares of GNTA opened at $3.84 on Monday. Genenta Science has a one year low of $2.20 and a one year high of $7.28. The stock has a 50-day moving average price of $4.06 and a 200 day moving average price of $4.54.

Genenta Science Company Profile

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter.